Israel's Equity Market Shows Resilience Amid Index Rebalancing

The iShares MSCI Israel ETF completed its index rebalancing on Feb 27, 2026, following $155M+ in net inflows and strong performance linked to Israel's record-setting stock market.

The iShares MSCI Israel ETF has completed its latest portfolio adjustment, aligning with the results of MSCI's semi-annual index review. This rebalancing, which took effect at the close on Friday, February 27, 2026, ensures the fund continues to accurately track the evolving Israeli stock market. The move comes after a period of notable stability and strong investor interest in Israeli equities, setting the stage for the fund's next phase.

Investor Confidence and Recent Performance

Recent data underscores significant investor optimism toward this market segment. In the month leading up to the rebalancing, the iShares MSCI Israel ETF attracted net inflows exceeding $155 million. This vote of confidence is supported by a robust performance track record; the fund has posted a gain of more than 8% since the start of the year. Despite a slight single-day decline of 0.36% on Friday, its net asset value (NAV) settled at a solid €118.70.

The underlying market strength is even more apparent in the broader TA-125 index, Israel's benchmark. Recently reaching an all-time high above 4,214 points, the index closed last Friday at 4,075 points. This level represents an impressive advance of over 60% during the preceding twelve-month period.

The Mechanics of the Index Update

The fund's composition is now updated to reflect the revised MSCI Israel Capped Investable Market Index. These periodic reviews are a standard mechanism to maintain an index's relevance, ensuring constituent weightings mirror the current market capitalization of companies. While the specific additions and deletions within the Israeli index were not detailed publicly, the rebalancing process guarantees the ETF remains tightly correlated with the nation's leading firms.

This particular adjustment was part of MSCI's wider global index review, which saw hundreds of securities worldwide added or removed across various indices. Market participants have been aware of the impending changes since their initial announcement on February 10, allowing ample time for portfolio repositioning.

A Concentrated Exposure to Key Sectors

The ETF provides targeted exposure to Israel's most critical industries, with a pronounced focus on pharmaceuticals and financial services. These sectors form the core of the portfolio, highlighted by significant holdings in Teva Pharmaceutical Industries Ltd. (9.46%), Bank Leumi, and Bank Hapoalim. This structure offers investors access to established Israeli blue-chip companies that are frequently underrepresented in global indices.

Outlook and Considerations

The completion of the February 27 rebalancing establishes a new baseline for the fund. Moving forward, market observers will monitor whether the TA-125 index can build momentum and challenge its recent record levels following a period of consolidation. While geopolitical uncertainties and their potential impact on factors like energy prices remain a focus for investors, the fundamental strength of the ETF's core holdings is likely to be a primary driver of performance in the coming weeks. The continued resilience of Israel's equity market in a challenging environment will be put to the test.